The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir-Reference-Cited by-同舟云学术

The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir

Published:2016-12-16 Issue:2 Volume:11 Page:103-113
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Hayes C. Nelson¹²,Imamura Michio¹²,Chayama Kazuaki¹²³

Affiliation:

1. Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan

2. Liver Research Project Center, Hiroshima University, Hiroshima, Japan

3. Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima, Japan

Funder

Research Program on Hepatitis from the Japan Agency for Medical Research and Development

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474124.2017.1270205

Reference93 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. The global burden of hepatitis C

3. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

4. Projecting future complications of chronic hepatitis C in the United States

5. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of serum IP‐10/CXCL10 measurement in predicting post‐direct acting antiviral treatment liver function in patients with HCV‐decompensated liver cirrhosis;Hepatology Research;2022-12-13

2. Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients;Journal of Clinical Biochemistry and Nutrition;2021

3. The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032);Topics in Medicinal Chemistry;2019

4. The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex;Topics in Medicinal Chemistry;2019

5. HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients;PLOS ONE;2017-12-07